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RegulatoryT cells (Treg) play a key role in maintaining the balance of immune responses in
human health and in disease. Treg come in many flavors and can utilize a variety of mech-
anisms to modulate immune responses. In cancer, inducible (i) or adaptive Treg expand,
accumulate in tissues and peripheral blood of patients, and represent a functionally promi-
nent component of CD4+T lymphocytes. Phenotypically and functionally, iTreg are distinct
from natural (n) Treg. A subset of iTreg expressing ectonucleotidases CD39 and CD73 is
able to hydrolyze ATP to 5′-AMP and adenosine (ADO) and thus mediate suppression of
those immune cells which express ADO receptors. iTreg can also produce prostaglandin
E2 (PGE2). The mechanisms responsible for iTreg-mediated suppression involve binding of
ADO and PGE2 produced by iTreg to their respective receptors expressed on T effector
cells (Teff), leading to the up-regulation of adenylate cyclase and cAMP activities in Teff
and to their functional inhibition.The potential for regulating these mechanisms by the use
of pharmacologic inhibitors to relieve iTreg-mediated suppression in cancer suggests the
development of therapeutic strategies targeting the ADO and PGE2 pathways.
Keywords: cancer inducible regulatoryT cells, natural regulatoryT cells, tumor microenvironment
INTRODUCTION
Regulatory T cells (Treg), a small subset of CD4+ T lymphocytes
(∼5%) in the peripheral blood, maintain immune responses in
balance and ensure that potentially dangerous excessive immune
reactivity is prevented. Treg specialize in suppressing responses
of other immune cells (1, 2). Recent attention to Treg has been
fueled by findings that implicate these cells in several human
diseases including cancer, chronic infections, and autoimmune
syndromes (3–5). While in health, thymus-derived natural (n) Treg
are responsible for peripheral tolerance and immune homeostasis,
their imbalance in disease appears to contribute to pathological
processes and thus, has been of great interest and importance.
Accumulating data suggest that human Treg comprise several dis-
tinct subsets of regulatory cells (6), introducing a possibility of a
complex regulatory network in which Treg participate but which
is orchestrated by factors that remain largely unknown. The ques-
tion of what or who regulates Treg has been often asked, remains
unanswered, and stimulates investigation into Treg interactions
with other immune and non-immune cells and into molecular
mechanisms underpinning these interactions. In cancer, for exam-
ple, Treg are thought to be involved in tumor escape from the host
immune system (4, 7). And although it is clear that Treg accu-
mulate in tumor tissues and the peripheral circulation of cancer
patients (7, 8), the role these Treg play in tumor progression or
regression has not been clear, and associations between the Treg
frequency and disease outcome remain a subject of a considerable
dispute (9). This is a clinically relevant dispute, because if Treg pro-
mote cancer progression by interfering with anti-tumor immunity,
they need to be muzzled. But if Treg down-regulate inflammatory
responses that may favor tumor progression, then their therapeutic
removal is contraindicated. At the heart of the controversy is a
notion that not all Treg are the same, that their diversity may be
environmentally regulated and that they represent a finely regu-
lated system of check and balances which could be therapeutically
manipulated to benefit the host. In this paper, we will present
evidence in support of this view of human Treg, addressing their
characteristics and functions in patients with cancer as well as
potential pharmacologic strategies for Treg regulation.
PROBLEMSWITH THE DETECTION AND ISOLATION OF
HUMAN TREG
Much of what is currently known about Treg comes from stud-
ies in the mouse. Human Treg are difficult to study for several
reasons. They are a minor subset of CD4+ T cells for which no
definite identifying marker exists. The FOXP3 transcription fac-
tor, which has been widely used to study murine Treg, is not a
reliable marker of human Treg, because it can be expressed by
activated CD4+ T effector cells (Teff) or tissue cells (10–12) and
may not be expressed in some activated Treg (13). Also, FOXP3 is
an intracellular factor and thus cannot be used for Treg isolation.
A high level of CD25 expression on the Treg cell surface is useful
in separating Treg from CD25neg cells but is neither specific for
Treg (activated CD4+ T cells are IL-2R+) nor particularly helpful
in flow cytometry, where a distinction between “high” and “inter-
mediate” IL-2R expression becomes arbitrary. Similarly, in situ
studies of Treg based on expression of FOXP3 in paraffin sections
or the CD4+CD25+ cell frequency in cryosections may not be
entirely reliable, and concerns exist that variable results for the
Treg frequency in various human tumors, for example, may be the
result of methodological differences rather than actual differences
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in cell counts. Negative selection of Treg based on low or absent
expression of CD127 (IL-7 receptor) is often used in mice for Treg
enrichment (14), but in man, it may not yield sufficient numbers of
high purity Treg. Other surface molecules known to be expressed
on Treg, including CTLA-4, GITR, PD-1, ICOS, and chemokine
receptors, CCR4, CCR6, and CCR7, endow these cells with special
functional characteristics (15–19) but are not specific to Treg and
therefore cannot be used for Treg enrichment or isolation. Thus,
there is a need for a Treg-specific surface marker that would allow
for the selective isolation of human Treg in numbers necessary for
their functional characterization.
The discovery of ectonucleotidases, CD39 and CD73, on the
surface of murine Treg (20, 21) has focused attention on these
enzymes as potential markers of Treg in man. Their expression on
the cell surface and enzymatic activity responsible for hydrolysis of
exogenous (e) ATP to 5′-AMP and adenosine (ADO) were attrac-
tive features which promised to facilitate studies of human Treg.
However, a more extensive evaluation of the distribution of these
ectoenzymes on human lymphocytes indicated that while CD39
expression was largely restricted to CD4+CD25highFOXP3+ T
cells, that of CD73 was not, as small subsets of CD4+ as well
as CD8+ T cells were found to be CD73+ but CD39neg (22). Fur-
thermore, only <1% of human Treg in the circulation of normal
donors co-expressed both enzymes on the cell surface as seen by
flow cytometry (23). In Western blots of sorted CD4+CD25high
Treg, weak expression of CD73 together with strong CD39 expres-
sion was detectable, suggesting an intracellular localization of
CD73. Relative levels of mRNA specific for these enzymes in the
isolated subsets of CD4+CD39+ and CD4+CD73+CD39neg T
cells also indicated the presence of low levels of mRNA for CD73
in the former and of mRNA for CD39 in the latter (23). Confocal
microscopy of permeabilized CD4+CD39+ cells showed CD39
evenly distributed on the cell surface, and only rare intracyto-
plasmic granular inclusions of CD73. In CD4+CD73+CD39neg
cells, granular distribution of CD73 in the cytosol was prominent,
and surface staining of CD4+CD25+ T cells for CD73 indicated
a cap-like staining pattern, suggestive of rapid stripping of this
molecule from the cell surface (23). This is in agreement with the
reported sensitivity of CD73, a dimer of two identical 70 KDa sub-
units anchored to the plasma membrane via a C-terminal serine
residue linked to glycophosphatidyl inositol (GPI), to proteolytic
cleavage (24). Thus, the absence of CD73 from the surface of
human CD4+CD39+ Treg may be explained by its rapid turnover
and removal from the cell surface associated with a concomitant
decrease in the number of intracytoplasmic granules in these cells
(23). The rapid utilization and removal of CD73 from the surface
of human Treg accompanied by the persistent and intense CD39
expression on their surface suggests that these cells are always
prepared to hydrolyze eATP to 5′-AMP, which may either accu-
mulate, signal via A1R expressed on Treg or Teff (25) or be further
hydrolyzed by CD73 to ADO, depending on the availability of this
enzyme on the cell surface. This suggests a carefully orchestrated
production of ADO by Treg and the existence of regulatory cellular
mechanisms responsible for maintaining collaboration between
the two ectoenzymes. Because CD39 is a stable, specific, and enzy-
matically active-surface marker of human Treg, whose expression
levels correlate with that of FOXP3 (26), it has been increasingly
often used as a phenotypic/functional marker appropriate for iso-
lation and enrichment of human Treg from human blood and
tissues (27).
HUMAN NATURAL (n) TREG VS. INDUCIBLE (i) TREG
Human Treg can be broadly divided into (a) thymus-derived nat-
ural (n) Treg which are present in the periphery of normal donors
and regulate tolerance to self and (b) adaptive or inducible (i)
Treg, which arise in response to cognate antigens presented by
antigen-presenting cells (APC) and expand in the microenviron-
ment enriched in the cytokines promoting Treg proliferation (7).
Natural (n) Treg constitutively express FOXP3 and the activation
marker CD25 (CD4+CD25highFOXP3+), originate in the thy-
mus by high-affinity interaction of the T-cell receptor (TcR) with
antigens expressed in the thymic stroma (28), and suppress pro-
liferation of Teff in a contact-dependent, cytokine-independent
manner (8). We believe that Treg which accumulate in the periph-
eral blood and tissues of patients with cancer largely represent
iTreg. These cells are induced in the periphery or at tissue/tumor
sites from the naïve CD4+CD25(−) T cells in the presence of
IL-10 or TGF-β (29) and exert suppression by the production of
soluble suppressor factors. Their suppressor functions may not
be associated with high levels of FOXP3 expression. These cells
are functionally heterogenous and may be broadly subdivided
into “activated” (CD25+FOXP3+) cells which express CD45RO
(i.e., have a memory phenotype) and “resting” CD45RA+ cells
which do not mediate suppression (6, 30–32). Different subsets
of iTreg have been recently identified that appear to be pheno-
typically and functionally distinct from other Treg. These include
CD4+CD39+ Treg involved in the ADO pathway (see above), IL-
35 producing iTreg (iTreg35) which do not express FOXP3 and
are independent of IL-10 or TGF-β (33) and the iTreg subsets that
express select chemokine receptors and mediate suppression of
only those Teff lineages that utilize the corresponding chemokines
(6). The emerging view of iTreg suggests that these Treg develop
and function in response to unique microenvironmental stim-
uli and represent a “tailor made” system of brakes and balances
needed to modulate different types of Th responses during inflam-
mation. Thus,various existing immunosuppressive pathways, such
as, e.g., the ADO pathway, seem to be able to recruit or induce iTreg
which undergo functional specialization resulting in the appear-
ance of Treg able to regulate this pathway. It remains unclear how
evolving inflammatory responses regulate this selective Treg spe-
cialization process or which environmental stimuli provoke its
progression.
CHARACTERISTICS OF IN VITRO GENERATED HUMAN iTREG
To be able to learn more about the precise mechanisms respon-
sible for the generation, phenotype, and functions of human
iTreg, we developed an in vitro assay system for their expansion.
Human CD4+CD25neg T cells and autologous immature den-
dritic cells (iDC) were co-incubated with irradiated tumor cells
and a cytokine mix containing IL-2, IL-10, and IL-15 (20 IU/mL
of each) for 10 days at 37 °C (34). The cells that outgrew in
these cultures gradually acquired phenotypic and functional char-
acteristics consistent with those of iTreg or Tr1 cells as initially
described in the literature (29). By day 10, most of proliferating
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T cells were CD3+CD4+CD25+IL-2Rβ+IL-2Rγ+FOXP3+IL-
10+TGF-β+IL-4(−), and they strongly suppressed proliferation
of autologous responder T cells (34). Using this well-defined
model system for the Tr1 generation, we investigated CD39 and
CD73 ectonucleotidase expression on these cells and their poten-
tial contribution to ADO-mediated suppression of Teff functions.
By flow cytometry and Western blots, most Tr1 cells co-expressed
CD39 and CD73 and efficiently hydrolyzed exogenous ATP to
ADO as shown in ATP consumption assays and by mass spec-
trometry for ADO (22). Further, in the presence of ARL67156,
a selective CD39 antagonist, or αβ-methylene ADP, an inhibitor
of CD73, Tr1-mediated suppression of proliferation of autolo-
gous CSFE-labeled CD4+CD25(−) responder T cells was signif-
icantly blocked, restoring the ability of these cells to proliferate
or produce cytokines (22). In aggregate, these in vitro data sug-
gested that human Tr1 co-expressing CD39 and CD73 could
produce immunosuppressive ADO and could exert strong sup-
pressive effects on Teff functions via engaging A2AR, as ZM241865,
a selective A2AR antagonist, reversed suppression mediated by
Tr1 (22). However, it remained unclear whether in vivo gener-
ated Tr1, presumably the major subset of iTreg in cancer patients,
also co-expressed these ectoenzymes. In the peripheral circulation
of normal donors, we and others consistently show expression of
CD39 on the surface of nearly all nTreg and of CD73 on only a
small (less than 1%) subset of these cells (23). This finding created
a need for an explanation of how CD39+ nTreg produce ADO and
mediate suppression in the absence CD73 on their surface. One
potential explanation may be that CD73 is present in the cytoplasm
of Treg and that its expression on the cell surface might be transient
and dependent on the state of cellular activation. Recently, we have
confirmed the presence of numerous CD73+ granules in the cyto-
plasm of circulating T and B lymphocytes by confocal microscopy
(23). We also showed that CD73 readily aggregates, forming caps
on the cells surface of nTreg, which contrasts with its prominent
and apparently less transient expression in the in vitro generated
iTreg (23). Further, we reported that CD4+ T cells expressing
CD39 or CD73 were present in tumor tissues (HNSCC), and
that at least some CD4+CD25+ Treg infiltrating these tumors
co-expressed the two markers in situ (13). Another possibility,
yet to be investigated, is that CD4+CD39+ Treg producing 5′-
AMP could signal via A1R and directly modulate activities of Teff,
because 5′-AMP has been shown to be an A1R agonist indepen-
dent on ectonucleotidases and capable of binding to A1R with an
affinity equal to or better than ADO (25). Also, we have recently
reported that a CD4+CD73+CD39(−) subset of T cells, most
CD19+B cells which are CD39+CD73+ and CD39+CD73+ exo-
somes isolated from the plasma of NC or cancer patients are all
good ADO producers in the presence of exogenous ATP (23). As
T cells, B cells, and exosomes are ubiquitous components in the
blood, body fluids, and tissues, we have suggested that they could
deliver membrane-tethered CD73 to enable CD39+ Treg to pro-
duce ADO. In fact, co-culture experiments in which CD4+CD39+
Treg were co-incubated with any of the CD73+ lymphocyte sub-
sets or exosomes carrying CD39 and CD73 confirmed the validity
of this cooperative mechanism for ADO production from eATP
(23). Exosomes carrying biologically active CD39 and CD73 were
isolated from the plasma of normal controls and were enriched in
the cancer patients’ body fluids, suggesting that exosomes derived
from CD73+ tumor cells in body fluids of cancer patients may be
an especially rich source of CD73 enabling CD4+CD39+ human
Treg to produce ADO. The role of exosomes in the regulation of
the ADO pathway by delivering their cargo to Treg is a new and
intriguing aspect of immune suppression in the tumor microenvi-
ronment, although exosomes obtained from the plasma of normal
donors also carry CD39 and CD73 ectonucleotidases.
ACCUMULATIONS OF iTREG IN MALIGNANCY
While nTreg develop in the thymus through a series of steps requir-
ing specific signals and transcription factors (2) de novo differenti-
ation from naïve CD4+CD25(−) T cells at mucosal sites or in the
tumor microenvironment also significantly contributes to the pool
of peripheral Treg. It has been well documented that the frequency
of circulating Treg is generally increased in patients with vari-
ous solid tumors or hematologic malignancies (9, 35). Also, Treg
percentages are substantially elevated among tumor infiltrating
lymphocytes (TIL). Furthermore, suppressive functions are usu-
ally much more evident in cancer-associated Treg relative to those
present in normal peripheral blood (8). The origin of Treg accu-
mulating in the cancer microenvironments is not clear. Increased
recruitment of Treg to tumor microenvironments, which is in part
mediated by tumor-derived chemokines and chemokine receptors
expressed by Treg (36), could result from enhanced proliferation
of Treg in response to tumor antigens or to Treg differentiation
and their prolonged survival induced by tumor-derived factors.
This potentially diverse origin of tumor-associated Treg might
be reflected in their heterogeneity and suggests that the Treg
phenotype and functions might be regulated by the local envi-
ronment. Thus, iTreg induced locally and expanded by soluble
factors secreted by tumors are likely to represent the majority of
suppressor lymphocytes present in the tumor milieu.
While iTreg which expand and accumulate at tumor sites are
expected to suppress anti-tumor immunity and thus favor tumor
progression, they also have the ability to block inflammatory
responses and thereby reduce or inhibit tumor growth. At present,
it is unclear whether blocking of tumor-induced inflammation
by iTreg is beneficial to the host. In some human solid tumors,
notably colorectal cancer and breast cancer, iTreg frequency and
activity in situ are reported to predict better outcome (37, 38). In
other solid tumors, Treg accumulations seem to be associated with
poor prognosis (39, 40). It remains to be determined whether Treg
accumulate and influence tumor progression or whether their fre-
quency simply serves as a prognostic marker with no functional
impact on cancer progression and outcome. In colorectal can-
cer, IL-17 expressing Treg subset exists within RORγt-expressing
Treg, and these cells expand in late stages of the disease (41).
These IL-RORγt-expressing Treg have the potential to produce
IL-17, are not suppressive but rather pro-inflammatory and are
pathogenic, as they promote disease progression in man and the
development of polyposis in mice (42). Expression of RORγt
by Treg has been associated with Treg plasticity, a loss of sup-
pressive properties, and conversion to Th-17 (41). Thus, cancer-
associated inflammation, at least in colon carcinoma, appears to
be controlled by the balance between suppressive Treg and pro-
inflammatory RORγt-expressing Treg, although the origin and
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regulatory elements driving the differentiation of these cell subsets
are not yet clear. Thus, there is a need for a better understanding
of the mechanisms responsible for Treg accumulations in cancer-
induced inflammation. This is a critically important question for
future cancer therapies aiming at the elimination of Treg as one
means of improving clinical responses.
TUMOR MICROENVIRONMENT AND HUMAN iTREG
Tumor-derived soluble factors, such as VEGF, SDF-1, IL-10, and
TGF-β, have been acknowledged to be responsible for expansion
of iTreg in tumor-bearing hosts (43, 44). Recently, the number
and variety of these factors have been increased to include tumor-
derived exosomes which carry death receptor ligands contributing
to apoptosis of activated CD8+ Teff (45) as well as a number of
other cytokines, chemokines and enzymes able to directly induce
expansion of Treg (46, 47). In addition, these factors induce accu-
mulation of immature DC which, in turn, promotes the expansion
of Treg, thereby contributing to inhibition of anti-tumor immune
responses (48). An enzyme, indoleamine 2,3-dioxygenase (IDO),
produced by DC is one of the most potent inducers of Treg dif-
ferentiation in the tumor milieu (49). The IDO activity results in
tryptophan depletion, leading to activation of the GCN2 kinase,
and to Treg expansion (50). The ligation of CTLA-4, which is
highly expressed on Treg, also leads to enhanced IDO production
and favors Treg expansion (51). In addition, the transcription fac-
tor, STAT3, as well as the immunosuppressive cytokine, TGF-β, are
abundant in the tumor microenvironment and can also contribute
to maintaining elevated IDO expression in DC or tumor cells.
In the tumor microenvironment, accumulating CD4+CD39+
iTreg expand upon induction by TA, DC products, and selected
cytokines and up-regulate CD73, acquiring the capability to uti-
lize ADO for mediating suppression of other immune cells. In
addition to the ADO pathway, another suppressive pathway is
known to operate in the microenvironment of many human solid
tumors which commonly overexpress cyclooxygenase-2 (COX-2).
PGE2 is a major product of COX-2 activity, and it too is a power-
ful immunosuppressive factor often implicated in human tumor
progression and poor outcome (52). We reported that in vitro
generated Tr1 were effective producers of PGE2 (53).
PGE2 AND iTREG
PGE2 mediates immune suppression via EP2 receptors (EP2R),
which are Gs protein-coupled receptors expressed on the surface
of immune cells. Similar to signals processed by ADO A2A recep-
tors (A2AR), PGE2 signaling leads to an increase in intracellular
levels and activation of 3′5′-cAMP in responder cells, with a con-
comitant decrease in cell proliferation and suppression of cytokine
production as well as other immune cell functions (54, 55). PGE2
also induces expansion of Tr1 cells and modulates their activity,
thus contributing to creating and sustaining a tolerogenic envi-
ronment (56). We showed that Tr1 proliferation as well as IL-10
and TGF-β production responsible for their suppressor functions
were dependent on COX-2 expression in tumor cells (56). When
COX-2 expression was inhibited in tumor cells, using siRNA spe-
cific for the COX-2 gene or diclofenac, a generic COX inhibitor,
Tr1 outgrowth, and suppressor functions were inhibited. Further,
tumor cells which overexpressed COX-2 induced a significantly
greater number of Tr1 than COX-2(−) tumor cells. Also, Tr1 gen-
erated in co-cultures with COX-2+ tumor cells were significantly
more suppressive, hydrolyzed more exogenous ATP, and produced
higher levels of ADO and PGE2 than Tr1 induced by COX-2(−)
tumors (56). Tr1 induced by COX-2+ tumor cells were themselves
COX-2+ and were able to produce and secrete PGE2. These COX-
2+ Tr1 co-expressed CD39 and CD73, and in addition to PGE2,
they also produced ADO (53). Suppressor functions of these Tr1
were blocked in the presence of ectonucleotidase antagonists and
also in the presence of indomethacin, confirming that ADO and
PGE2 contributed to Tr1-mediated immunosuppression (53).
ADO AND PGE2 COLLABORATE IN MEDIATING
SUPPRESSION IN THE TUMOR ENVIRONMENT
Since many human solid tumors and Tr1 generated in the presence
of these tumors produce ADO and PGE2, the tumor microenvi-
ronment tends to be immunosuppressive. The G-protein-coupled
ADO and PGE2 receptors on responder lymphocytes mediate
signaling via 3′,5′-cAMP, and the two factors can cooperate in
suppressing functions of immune cells (see Figure 1). By adding
AH6809, an EP2R antagonist to co-cultures of Tr1 and Teff, we
showed that PGE2 binds to EP2R on lymphocytes (53). Antag-
onists of EP1, EP3, or EP4 receptors had no effect on Teff pro-
liferation in these co-cultures. Also, studies with ZM241385, an
antagonist of A2AR, showed that suppression of Teff prolifera-
tion by Tr1-derived ADO was prevented in the presence of this
inhibitor, confirming the utilization of A2AR on Teff by ADO.
In these co-culture experiments, ADO and PGE2 appeared to be
equally involved in suppression of Teff proliferation by iTreg, as
antagonists of EP2 and of A2 receptors equally reversed iTreg-
mediated suppression (53). As indicated in Figure 1, both ADO
and PGE2 down-modulate Teff functions by controlling 3′5′-
cAMP levels in these cells, presumably by engaging the adenylate
cyclase-7 (Ac-7), an Ac isoform present in lymphoid cells (57), as
also suggested by our preliminary data (Whiteside and Jackson).
This enzyme appears to be a point of convergence for EP2R and
A2AR, and it contributes to the regulation of 3′,5′cAMP levels in
responder cells. Downstream from Ac-7, the protein kinase type
I (PKA type I) in effector T cells is also involved in mediating
suppressor activity of ADO and PGE2 (22). We have shown that
Rp-8-Br-cAMPS, an agent which blocks binding of 3′5′-cAMP to
the regulatory subunit of PKA type I, significantly inhibited iTreg-
mediated suppression of Teff proliferation (53). This observation
suggests that blocking of PKA type I activity in Teff could protect
them from suppression delivered by ADO- and PGE2-producing
iTreg.
To determine whether ADO and PGE2 play a role in the
suppressive activity of Treg in vivo, we measured the frequency
of circulating CD39+ and COX-2+ Treg by flow cytometry in
cohorts of patients with HNSCC at various disease stages (8, 53,
Schuler et al., in revision). The frequency of CD39+ or COX-
2+ Treg was increased in these patients’ blood (relative to that
in NC), and it correlated with disease progression (8, 23, 58,
Schuler et al., in revision). Suppressor function of these Treg was
also significantly increased (8). Further, co-expression of CD39
and COX-2 in iTreg present among TIL in HNSCC tissues was
observed by immunohistochemistry (22). Our data support the
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FIGURE 1 | ADO and PGE2 collaborate in mediating suppression in the
tumor microenvironment. Inducible (i)Treg are activated in the tumor
microenvironment, co-express CD39 and CD73, and produce ADO via
hydrolysis of exogenous ATP/ADP. These Treg also up-regulate COX-2
expression and produce PGE2. These two factors, ADO and PGE2, are
abundant in the tumor microenvironment, which is strongly
immunosuppressive. The G-protein-coupled ADO and PGE2 receptors on
responder T cells receive and process the cognate signals that activate
adenylate cyclase-7 (AC-7) and lead to an increase in intracellular levels and
activation of 3′,5′-cAMP. This results in suppression of cellular functions in
responder T cells. The cooperation between ADO and PGE2 is mediated at the
level of the AC-7, which together with cellular phosphodiesterase (PDE4) is
responsible for regulating 3′,5′-cAMP levels in cells. The ADO and
PGE2-mediated cooperative inhibition of T effector functions via up-regulation
of 3′,5′-cAMP levels represents one of the mechanisms utilized by iTreg for
inducing immune suppression.
conclusion that iTreg present in the blood and tumor tissues of
patients with cancer co-express CD39 and COX-2 and have the
capability to produce ADO and PGE2. While CD39 and COX-2
were co-expressed in circulating CD4+T cells of HNSCC patients,
IL-10 and TGF-β were expressed by a non-overlapping, distinct
subset of CD4+ T cells. These data suggested that Treg pro-
ducing ADO and PGE2 may be distinct from the Treg subset
expressing IL-10 and TGF-β. Further, in HNSCC patients success-
fully treated with chemoradiotherapy (CRT) and evaluated during
post-therapy clinical remission, only CD39+, but not IL-10+ or
TGF-β+ Treg, were found to be expanded and to accumulate.
This CD4+CD39+ subset of Treg was shown to be resistant to
CRT, persisted in the patients’ circulation for months after CRT
and mediated high levels of immune suppression (Schuler et al.,
in revision). This observation suggests that CD39+ iTreg might
be of special clinical significance in vivo, because their suppres-
sive activity could facilitate the disease recurrence. In HNSCC, the
disease recurrence within 2–3 years of successful oncological ther-
apies occurs in a large proportion (50–60%) of patients. Therefore,
the possibility that CD39+ iTreg contribute to early recurrence by
inhibiting anti-tumor immune responses is being further investi-
gated at our institution in a prospective non-therapeutic clinical
trial.
If ADO and PGE2 produced by activated iTreg synergize in
mediating suppression of conventional T cell functions, the result
of such synergy is powerful immune suppression of immune cells.
Because human tumors are often COX-2+ and are rich in extracel-
lular ATP due to cell death, opportunities exist for ATP-mediated
up-regulation of ectonucleotidase activities and COX-2 expression
in iTreg generated and accumulating in the tumor microenviron-
ment. In fact, up-regulation in expression and activity of these
enzymes is known to occur during inflammation, which is a fre-
quent component of the tumor development (54, 59). The cooper-
ation between the ADO and PGE2 pathways, which is regulated at
the 3′,5′-cAMP level, is an example of a powerful suppressor mech-
anism which, by down-regulating anti-tumor immune responses,
contributes to tumor progression, and tumor escape from immune
control.
ADO- AND PGE2-PRODUCING iTREG AS PHARMACOLOGIC
TARGETS IN CANCER
A number of clinically applicable pharmacologic interventions
exist for direct interference with the production of ADO and/or
PGE2 or with binding to their cognate receptors on immune cells.
Pharmacologic interventions have been used to block undesirable
suppressive effects of these factors in diseases other than cancer
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(58, 60, 61). The inhibitors of the PGE2 pathway (e.g., celecoxib
or indomethacin, diclofenac, ibuprofen) have been previously
utilized in cancer therapy (61). However, the application of phar-
macologic inhibitors to specifically target iTreg accumulating in
cancer is a novel therapeutic strategy. To date, Treg depletion
has depended on the delivery to tumor-bearing hosts of low-dose
cyclophosphamide, daclizumab (anti-CD25 Ab), denileukin difti-
tox (ONTAC), or tyrosine kinased inhibitors such as sunitinib
(62–64). Largely utilized to diminish suppression and improve
endogenous anti-tumor immunity, these agents have transient
and inconsistent effects on the Treg frequency and functions.
More recent use in the clinic of ipilimumab or anti PD-1/PDL-
1 Abs, which target T-cell checkpoints including those operat-
ing in Treg, might be more effective in controlling suppression,
but their effectiveness is still being evaluated. In patients with
cancer, iTreg able to produce ADO and PGE2 accumulate in
tissues and blood and may be resistant to conventional onco-
logical therapies (Schuler et al., in revision), so that silencing of
these cells appears to be advisable. Pharmacologic agents such as
inhibitors of ectonucleotidase activity, A2AR or EP2R antagonists
or inhibitors of PKA type I activity can effectively block suppres-
sion mediated by iTreg, as shown in our in vitro experiments (22).
In addition, rolipram, a phosphodiesterase 4 (PDE4) inhibitor,
increased 3′,5′-cAMP levels in Teff thereby increasing their sus-
ceptibility to iTreg-mediated suppression (53). Drugs blocking
COX-2 activity are in clinical use and can be readily selected for
blocking PGE2 production by iTreg and thus prevent suppres-
sion of Teff. With evidence pointing to A2AR and EP2R as the
negative signal-mediating receptors in lymphocytes, it might be
rational to design the pharmacologic blockade specifically target-
ing these receptors. Alternatively, the selective blockade in Teff
of Ac-7, which is the convergence point for ADO and PGE2 sig-
naling, is expected to restore anti-tumor activity in patients with
cancer (65, 66). Because the Ac-7 isoform integrates signals gener-
ated by both ADO and PGE2 pathways and are expressed mainly,
perhaps exclusively, in hematopoietic cells (67), it represents a
potentially attractive therapeutic target. Inhibition of Ac-7 activ-
ity by pharmacologic agents could be confined to lymphocytes,
leading to selective down-regulation of 3′,5′-cAMP levels in Teff,
up-regulation of Teff functions, silencing of iTreg and relief from
ADO- and PGE2-mediated suppression. Unfortunately, among the
available pharmacologic inhibitors of Ac none is specific for the Ac-
7 isoform, and further development is necessary for implementing
the simultaneous blockade of ADO and PGE2 pathways at the
point of their convergence. Nevertheless, this remains an attrac-
tive possibility for restoration of immune competence in cancer
and represents a novel strategy for “blocking the inhibitors” with
pharmacologic agents.
Yet another pharmacologic intervention that could lead to
restoration of anti-tumor immunity involves the PDE pathway
in Teff. Levels of 3′,5′-cAMP in Teff are partly determined by the
activity of PDEs, and its up-regulation with, e.g., propanolol, lead-
ing to a decrease in cAMP levels, can be expected to restore Teff
functions and decrease Treg-mediated suppression. A recent study
in mice, illustrated the in vivo effectiveness of a PDE-directed phar-
macologic strategy (68). Bushell et al. showed that stimulation of
CD4+ T cells by allogeneic DC in the presence of cilostamide, an
inhibitor of PDE3, resulted in a significant increase in the num-
ber and functions of Treg, which blocked allograft rejection (68).
This in vivo study confirms that modulation of PDE activity is a
promising strategy for controlling functions of Treg.
CONCLUSION
Among suppressive mechanisms utilized by Treg in patients with
cancer, ADO- and PGE2-mediated suppression appears to be espe-
cially prominent. These factors are present in the tumor microen-
vironment not only because many human tumors produce them
but also because activated iTreg, the subtype of Treg accumulat-
ing in tissues and the peripheral circulation of cancer patients, are
also ADO and PGE2 producers. iTreg express enzymes involved
in ATP hydrolysis and PGE2 production, and utilize ADO and
PGE2 to up-regulate 3′5′-cAMP in Teff suppressing their func-
tions. Pharmacologic interventions designed to selectively target
components of the ADO and/or PGE2 pathways could not only
inhibit the tumor-derived factors but also to silence suppres-
sive functions of Treg and thus restore anti-tumor activity of
Teff. A particularly attractive therapeutic strategy for overcoming
tumor-induced immune suppression and prevent tumor escape
involves a blockade by pharmacologic agents of cooperative inter-
actions between ADO and PGE2. Pharmacologic blocking of this
cooperation, which is mediated via the Ac-7 isoform present in
lymphocytes and responsive to A2A and EP2 receptor signaling,
depends on the future development of small molecular weight
selective inhibitors of Ac-7 activity. The resulting alterations in
cAMP levels in Teff could restore their anti-tumor functions and
silence Treg in cancer.
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